CDSCO nod to AstraZeneca Pharma India to import, sell lung cancer treatment medicine Ruchika Sharma3 March 2025 4:26 PM ISTAstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control Organisation, Directorate...
Expansion of warning statement may be considered after submission of first year PSUR data: CDSCO panel on AstraZeneca's anticancer drug Dr. Divya Colin25 Jun 2024 10:28 PM ISTNew Delhi: Noting that Tremelimumab Concentrate for Solution for infusion 20 mg/ml is not yet launched in the Indian market, the Subject Expert...
CDSCO nod to AstraZeneca cancer drug Tremelimumab Ruchika Sharma2 Jun 2023 11:53 AM ISTThe approval paves the way for the launch of Tremelimumab solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single-dose vials) in...
Imfinzi plus Imjudo approved in EU for patients with advanced liver and non small cell lung cancers: AstraZeneca Ruchika Sharma25 Feb 2023 10:00 AM ISTUK: AstraZeneca has announced that Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations have been approved in the European Union...
AstraZeneca gets Japanese approval for Imfinzi, Imjudo to treat 3 types of cancer Ruchika Sharma28 Dec 2022 11:30 AM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca gets USFDA nod for Imfinzi, Imjudo with chemotherapy to treat metastatic non-small cell lung cancer Ruchika Sharma11 Nov 2022 2:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca gets CDSCO nod to conduct Phase III CT of antineoplastic FDCs drug Dr. Divya Colin24 May 2022 10:45 AM ISTNew Delhi: Suggesting to increase the number of subjects in clinical trial to 34, from the proposed 24 subjects in India, the Subject Expert Committee...
